VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 52,788 shares, an increase of 88.7% from the April 15th total of 27,969 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average trading volume of 61,296 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of VivoSim Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, VivoSim Labs currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.23% of the company’s stock.

VivoSim Labs Trading Up 0.6%

NASDAQ VIVS traded up $0.01 during trading on Monday, hitting $1.30. The company had a trading volume of 9,685 shares, compared to its average volume of 1,099,393. VivoSim Labs has a one year low of $1.25 and a one year high of $5.30. The company has a market cap of $3.39 million, a price-to-earnings ratio of -0.41 and a beta of 1.41. The company’s fifty day moving average is $1.58 and its 200-day moving average is $1.93.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.